Logo

Sensorion Receives Approval to Commence P-I/II Study of SENS-501 (OTOF-GT) for Hearing Impairment Across European Countries

Share this
Sensorion

Sensorion Receives Approval to Commence P-I/II Study of SENS-501 (OTOF-GT) for Hearing Impairment Across European Countries

Shots:

  • Sensorion has received approval for its Clinical Trial Application (CTA) to commence a P-I/II study of SENS-501 (OTOF-GT), based on preclinical studies to evaluate the safety and efficacy, in France
  • The P-I/II (Audiogene) study will assess the safety, tolerability, and efficacy of SENS-501 for treating OTOF gene-mediated hearing impairment in pediatric patients 6-31mos. of age. Information about the first patient is anticipated in H2’24
  • SENS-501 (OTOF-GT) dual vector AAV gene therapy is developed to restore hearing in individuals with mutations in the gene coding for otoferlin protein who have severe to profound sensorineural prelingual non-syndromic hearing loss

Ref: Sensorion | Image: Sensorion

Related News:- Sensorion’s SENS-401 Receives Australia’s Approval for the Initiation of Proof-of-Concept Trial to Treat Hearing Impairment

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions